Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SUNIL GUPTA

Allopathic & Osteopathic Physicians Ophthalmology Retina Specialist

NPI
1063489383
CMS profile
48440
Location
PENSACOLA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$12,535.18

54 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $9,326.25 2
Food and Beverage $1,827.91 47
Travel and Lodging $1,381.02 5

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 2; records 51–54 of 54 matching records. This page contains 4 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SUNIL GUPTA

NPI 1063489383 · CMS profile ID 48440

Allopathic & Osteopathic Physicians / Ophthalmology / Retina Specialist

PENSACOLA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–54 of 54 matching records. This page contains 4 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1063489383?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SUNIL GUPTA, NPI 1063489383, CMS profile ID 48440. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–54 of 54 matching records. This page contains 4 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1063489383?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). SUNIL GUPTA, NPI 1063489383, CMS profile ID 48440. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–54 of 54 matching records. This page contains 4 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1063489383?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
SUNIL GUPTA, NPI 1063489383, CMS profile ID 48440, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–54 of 54 matching records. This page contains 4 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1063489383?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

54 matching records · $12,535.18 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 54 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–54 of 54.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ABBVIE INC. $24.5202/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103853895 CMS
Genentech USA, Inc. $3.0901/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133119227 CMS
Genentech USA, Inc. $5.3101/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133119235 CMS
Genentech USA, Inc. $32.3901/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133119231 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $364,768.04 45
PY2020 $300,719.41 17
PY2021 $858,155.46 25
PY2022 $274,038.64 43
PY2023 $1,237.05 39
PY2024 $12,535.18 54
PY2025 $4,949.48 27

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $710,328.67 282
PY2024 Principal investigator $335,702.11 68
PY2023 Recipient $54,161.00 6
PY2023 Principal investigator $800,850.64 129
PY2022 Principal investigator $1,169,727.99 82
PY2021 Principal investigator $1,130,741.57 70
PY2020 Recipient $1,004.29 1
PY2020 Principal investigator $1,287,721.89 88
PY2019 Principal investigator $876,393.75 65

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

282 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Ocular Therapeutix, Inc. $16,884.90 12/24/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239881
Principal investigator 1 Ocular Therapeutix, Inc. $6,031.80 12/24/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239883
Principal investigator 1 Ocular Therapeutix, Inc. $1,469.89 12/24/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239885
Principal investigator 1 Ocular Therapeutix, Inc. $2,925.00 12/24/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239887
Principal investigator 1 Janssen Research & Development, LLC $14,325.00 12/15/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC
Long-term Extension Study for Participants with Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) in JNJ-81201887 Parent Clinical Studies No dispute reported 06/30/2026 1175394424
Principal investigator 1 Genentech, Inc. $2,283.00 12/11/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211660767
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,715.11 12/11/2025 Non-covered Recipient Entity
RETINA SPECIALTY INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184273353
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,902.03 12/11/2025 Non-covered Recipient Entity
RETINA SPECIALTY INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184273355
Principal investigator 1 Ocular Therapeutix, Inc. $444.71 12/05/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239879
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,947.96 12/01/2025 Non-covered Recipient Entity
RETINA SPECIALTY INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184267283
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 11/20/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660713
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 11/20/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660717
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 11/20/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660721
Principal investigator 1 Ocular Therapeutix, Inc. $6,031.80 11/19/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239877
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,902.03 11/19/2025 Non-covered Recipient Entity
RETINA SPECIALTY INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184262327
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,902.03 11/19/2025 Non-covered Recipient Entity
RETINA SPECIALTY INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184262329
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $78.00 11/14/2025 Non-covered Recipient Entity
RETINA SPECIALTY INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184260805
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $78.00 11/14/2025 Non-covered Recipient Entity
RETINA SPECIALTY INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184260807
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $78.00 11/14/2025 Non-covered Recipient Entity
RETINA SPECIALTY INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184260809
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $78.00 11/14/2025 Non-covered Recipient Entity
RETINA SPECIALTY INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184260811
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $78.00 11/14/2025 Non-covered Recipient Entity
RETINA SPECIALTY INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184260813
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $78.00 11/14/2025 Non-covered Recipient Entity
RETINA SPECIALTY INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184260815
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $78.00 11/14/2025 Non-covered Recipient Entity
RETINA SPECIALTY INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184260817
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $78.00 11/14/2025 Non-covered Recipient Entity
RETINA SPECIALTY INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184260819
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $78.00 11/14/2025 Non-covered Recipient Entity
RETINA SPECIALTY INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184260821
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $78.00 11/14/2025 Non-covered Recipient Entity
RETINA SPECIALTY INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184260823
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $78.00 11/14/2025 Non-covered Recipient Entity
RETINA SPECIALTY INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184260825
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $78.00 11/14/2025 Non-covered Recipient Entity
RETINA SPECIALTY INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184260827
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $78.00 11/14/2025 Non-covered Recipient Entity
RETINA SPECIALTY INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184260829
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $78.00 11/14/2025 Non-covered Recipient Entity
RETINA SPECIALTY INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184260831
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $78.00 11/14/2025 Non-covered Recipient Entity
RETINA SPECIALTY INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184260833
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $78.00 11/14/2025 Non-covered Recipient Entity
RETINA SPECIALTY INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184260835
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $78.00 11/14/2025 Non-covered Recipient Entity
RETINA SPECIALTY INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184260837
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $78.00 11/14/2025 Non-covered Recipient Entity
RETINA SPECIALTY INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184260839
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $78.00 11/14/2025 Non-covered Recipient Entity
RETINA SPECIALTY INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184260841
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $78.00 11/14/2025 Non-covered Recipient Entity
RETINA SPECIALTY INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184260843
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $78.00 11/14/2025 Non-covered Recipient Entity
RETINA SPECIALTY INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184260845
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $78.00 11/14/2025 Non-covered Recipient Entity
RETINA SPECIALTY INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184260847
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $78.00 11/14/2025 Non-covered Recipient Entity
RETINA SPECIALTY INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184260849
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $78.00 11/14/2025 Non-covered Recipient Entity
RETINA SPECIALTY INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184260851
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $78.00 11/14/2025 Non-covered Recipient Entity
RETINA SPECIALTY INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184260853
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $78.00 11/14/2025 Non-covered Recipient Entity
RETINA SPECIALTY INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184260855
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $78.00 11/14/2025 Non-covered Recipient Entity
RETINA SPECIALTY INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184260857
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $78.00 11/14/2025 Non-covered Recipient Entity
RETINA SPECIALTY INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184260859
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $78.00 11/14/2025 Non-covered Recipient Entity
RETINA SPECIALTY INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184260861
Principal investigator 1 Ocular Therapeutix, Inc. $5,403.60 11/12/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239873
Principal investigator 1 Ocular Therapeutix, Inc. $6,506.10 11/12/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239875
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,412.00 11/07/2025 Non-covered Recipient Entity
Sunil Gupta MD LLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364095
Principal investigator 1 Ocular Therapeutix, Inc. $1,460.99 11/07/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239871
Principal investigator 1 Ocular Therapeutix, Inc. $15,255.00 10/31/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239869
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,902.03 10/29/2025 Non-covered Recipient Entity
RETINA SPECIALTY INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184255193
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,902.03 10/29/2025 Non-covered Recipient Entity
RETINA SPECIALTY INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184255195
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,902.03 10/29/2025 Non-covered Recipient Entity
RETINA SPECIALTY INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184255197
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,902.03 10/29/2025 Non-covered Recipient Entity
RETINA SPECIALTY INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184255199
Principal investigator 1 Genentech, Inc. $6,617.00 10/17/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
Port Delivery System of Ranibizumab Extension Study No dispute reported 06/30/2026 1211660764
Principal investigator 1 Ocular Therapeutix, Inc. $200.00 10/09/2025 Non-covered Recipient Entity
Retina Specialty Institute - Pensacola
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250238337
Principal investigator 1 Ocular Therapeutix, Inc. $9,552.60 10/08/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239867
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,902.03 10/03/2025 Non-covered Recipient Entity
RETINA SPECIALTY INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184246225
Principal investigator 1 Ocular Therapeutix, Inc. $12,467.70 10/01/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239863
Principal investigator 1 Ocular Therapeutix, Inc. $1,905.70 10/01/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239865
Principal investigator 1 Genentech, Inc. $11,364.00 09/26/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS No dispute reported 06/30/2026 1211660755
Principal investigator 1 Genentech, Inc. $1,346.00 09/26/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211660760
Principal investigator 1 Ocular Therapeutix, Inc. $500.00 09/26/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239861
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,064.48 09/24/2025 Non-covered Recipient Entity
RETINA SPECIALTY INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184242399
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,064.48 09/24/2025 Non-covered Recipient Entity
RETINA SPECIALTY INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184242401
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,064.48 09/24/2025 Non-covered Recipient Entity
RETINA SPECIALTY INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184242403
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,863.22 09/24/2025 Non-covered Recipient Entity
RETINA SPECIALTY INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184242405
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,064.48 09/24/2025 Non-covered Recipient Entity
RETINA SPECIALTY INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184242407
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,863.22 09/24/2025 Non-covered Recipient Entity
RETINA SPECIALTY INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184242409
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,064.48 09/24/2025 Non-covered Recipient Entity
RETINA SPECIALTY INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184242411
Principal investigator 1 Ocular Therapeutix, Inc. $500.00 09/12/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239859
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,970.00 09/10/2025 Non-covered Recipient Entity
Sunil Gupta MD LLC
An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD No dispute reported 06/30/2026 1250364093
Principal investigator 1 Ocular Therapeutix, Inc. $3,300.00 09/03/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239857
Principal investigator 1 Ocular Therapeutix, Inc. $4,021.20 08/29/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239855
Principal investigator 1 ABBVIE INC. $5,807.00 08/27/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC
Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy No dispute reported 06/30/2026 1202506115
Principal investigator 1 Ocular Therapeutix, Inc. $6,666.30 08/20/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239851
Principal investigator 1 Ocular Therapeutix, Inc. $27,424.80 08/20/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239853
Principal investigator 1 Ocular Therapeutix, Inc. $424.53 08/15/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239849
Principal investigator 1 Ocular Therapeutix, Inc. $1,894.42 08/13/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239847
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,863.22 08/06/2025 Non-covered Recipient Entity
RETINA SPECIALTY INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184224716
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,863.22 08/06/2025 Non-covered Recipient Entity
RETINA SPECIALTY INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184224718
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,863.22 08/06/2025 Non-covered Recipient Entity
RETINA SPECIALTY INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184224720
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,863.22 08/06/2025 Non-covered Recipient Entity
RETINA SPECIALTY INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184224722
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,863.22 08/06/2025 Non-covered Recipient Entity
RETINA SPECIALTY INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184224724
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,863.22 08/06/2025 Non-covered Recipient Entity
RETINA SPECIALTY INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184224726
Principal investigator 1 Ocular Therapeutix, Inc. $6,031.80 07/30/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239845
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $54.07 07/23/2025 Non-covered Recipient Entity
Retina Specialty Institute-Pensacola
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225408758
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,412.00 07/16/2025 Non-covered Recipient Entity
Sunil Gupta MD LLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364083
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,412.00 07/16/2025 Non-covered Recipient Entity
Sunil Gupta MD LLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364085
Principal investigator 1 Ocular Therapeutix, Inc. $12,768.00 07/16/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239843
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,863.22 07/16/2025 Non-covered Recipient Entity
RETINA SPECIALTY INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184216250
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,619.22 07/16/2025 Non-covered Recipient Entity
RETINA SPECIALTY INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184216252
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,619.22 07/16/2025 Non-covered Recipient Entity
RETINA SPECIALTY INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184216254
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,619.22 07/16/2025 Non-covered Recipient Entity
RETINA SPECIALTY INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184216256
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,619.22 07/16/2025 Non-covered Recipient Entity
RETINA SPECIALTY INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184216258
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $75.00 07/10/2025 Non-covered Recipient Entity
RETINA SPECIALTY INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184213802
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $75.00 07/10/2025 Non-covered Recipient Entity
RETINA SPECIALTY INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184213804
Principal investigator 1 Ocular Therapeutix, Inc. $1,469.89 07/09/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239841
Principal investigator 1 Genentech, Inc. $10,509.00 07/07/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
Port Delivery System of Ranibizumab Extension Study No dispute reported 06/30/2026 1211660750
Principal investigator 1 Ocular Therapeutix, Inc. $11,563.20 07/02/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239839
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,863.22 06/30/2025 Non-covered Recipient Entity
RETINA SPECIALTY INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184212207
Principal investigator 1 Genentech, Inc. $13,758.00 06/25/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS No dispute reported 06/30/2026 1211660725
Principal investigator 1 Genentech, Inc. $3,788.00 06/25/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211660734
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $4,559.80 06/24/2025 Non-covered Recipient Entity
Retina Specialty Institute-Pensacola
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225407872
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,758.80 06/24/2025 Non-covered Recipient Entity
Retina Specialty Institute-Pensacola
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225407960
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $4,559.80 06/24/2025 Non-covered Recipient Entity
Retina Specialty Institute-Pensacola
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225408238
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $4,559.80 06/24/2025 Non-covered Recipient Entity
Retina Specialty Institute-Pensacola
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225408338
Principal investigator 1 Genentech, Inc. $2,283.00 06/23/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211660730
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660259
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660263
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660267
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660272
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660275
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660278
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660282
Principal investigator 1 F. Hoffmann-La Roche AG $1,139.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660286
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660291
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660295
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660300
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660304
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660308
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660311
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660314
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660318
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660322
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660326
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660328
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660332
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660336
Principal investigator 1 F. Hoffmann-La Roche AG $1,139.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660339
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660343
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660347
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660351
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660356
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660360
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660364
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660368
Principal investigator 1 F. Hoffmann-La Roche AG $1,139.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660371
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660374
Principal investigator 1 F. Hoffmann-La Roche AG $190.40 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660378
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660382
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660386
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660391
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660396
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660400
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660405
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660408
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660412
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660415
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660418
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660422
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660427
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660429
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660432
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660436
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660441
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660446
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660451
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660454
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660459
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660463
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660467
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660470
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660473
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660478
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660482
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660486
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660490
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660494
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660498
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660502
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660506
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660511
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660515
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660520
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660523
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660527
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660530
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660535
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660539
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660543
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660547
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660550
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660555
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660558
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660561
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660564
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660566
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660569
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660573
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660577
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660580
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660583
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660587
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660591
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660595
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660598
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660601
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660605
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660607
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660610
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660613
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660616
Principal investigator 1 F. Hoffmann-La Roche AG $69.30 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660620
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660625
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660629
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660632
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660636
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660639
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660643
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660646
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660651
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660655
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660658
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660662
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660665
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660668
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660672
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660680
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660686
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660691
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660697
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660700
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660703
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660706
Principal investigator 1 F. Hoffmann-La Roche AG $272.00 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211660709
Principal investigator 1 Ocular Therapeutix, Inc. $7,222.50 06/18/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239811
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,610.44 06/06/2025 Non-covered Recipient Entity
Retina Specialty Institute-Pensacola
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1225407964
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $54.07 06/06/2025 Non-covered Recipient Entity
Retina Specialty Institute-Pensacola
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1225407982
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,596.84 06/06/2025 Non-covered Recipient Entity
Retina Specialty Institute-Pensacola
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1225408230
Principal investigator 1 Ocular Therapeutix, Inc. $1,469.89 06/06/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239809
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,863.22 06/02/2025 Non-covered Recipient Entity
RETINA SPECIALTY INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184201223
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,863.22 06/02/2025 Non-covered Recipient Entity
RETINA SPECIALTY INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184201225
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,863.22 06/02/2025 Non-covered Recipient Entity
RETINA SPECIALTY INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184201227
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,863.22 06/02/2025 Non-covered Recipient Entity
RETINA SPECIALTY INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184201229
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,863.22 06/02/2025 Non-covered Recipient Entity
RETINA SPECIALTY INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184201231
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,619.22 06/02/2025 Non-covered Recipient Entity
RETINA SPECIALTY INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184201763
Principal investigator 1 Ocular Therapeutix, Inc. $7,038.00 05/28/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239807
Principal investigator 1 Ocular Therapeutix, Inc. $10,125.90 05/16/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239805
Principal investigator 1 Ocular Therapeutix, Inc. $4,241.32 05/14/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239803
Principal investigator 1 Ocular Therapeutix, Inc. $4,021.20 04/30/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239801
Principal investigator 1 Ocular Therapeutix, Inc. $49,644.00 04/23/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239799
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,863.22 04/23/2025 Non-covered Recipient Entity
RETINA SPECIALTY INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184188087
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,863.22 04/23/2025 Non-covered Recipient Entity
RETINA SPECIALTY INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184188089
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,863.22 04/23/2025 Non-covered Recipient Entity
RETINA SPECIALTY INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184188091
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,337.42 04/23/2025 Non-covered Recipient Entity
RETINA SPECIALTY INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184188093
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,863.22 04/23/2025 Non-covered Recipient Entity
RETINA SPECIALTY INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184188095
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,337.42 04/23/2025 Non-covered Recipient Entity
RETINA SPECIALTY INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184188097
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,863.22 04/23/2025 Non-covered Recipient Entity
RETINA SPECIALTY INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184188099
Principal investigator 1 Ocular Therapeutix, Inc. $8,350.40 04/16/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239797
Principal investigator 1 Genentech, Inc. $6,651.00 04/11/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS No dispute reported 06/30/2026 1211660738
Principal investigator 1 Ocular Therapeutix, Inc. $8,350.40 04/11/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239793
Principal investigator 1 Ocular Therapeutix, Inc. $8,350.40 04/11/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239795
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,000.00 04/07/2025 Non-covered Recipient Entity
Retina Specialty Institute-Pensacola
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1225403879
Principal investigator 1 Janssen Research & Development, LLC $698.00 04/07/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC
Long-term Extension Study for Participants with Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) in JNJ-81201887 Parent Clinical Studies No dispute reported 06/30/2026 1175394401
Principal investigator 1 Ocular Therapeutix, Inc. $2,436.00 03/28/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239829
Principal investigator 1 Ocular Therapeutix, Inc. $1,596.00 03/28/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239831
Principal investigator 1 Ocular Therapeutix, Inc. $8,000.00 03/28/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239833
Principal investigator 1 Ocular Therapeutix, Inc. $5,148.80 03/28/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239835
Principal investigator 1 Ocular Therapeutix, Inc. $8,633.20 03/28/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239837
Principal investigator 1 Genentech, Inc. $17,498.00 03/26/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211660742
Principal investigator 1 Genentech, Inc. $6,415.00 03/26/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC DBA RETINA SPECIALTY INSTITUTE
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211660747
Principal investigator 1 Ocular Therapeutix, Inc. $12,063.60 03/26/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239827
Principal investigator 1 Ocular Therapeutix, Inc. $3,000.00 03/19/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239815
Principal investigator 1 Ocular Therapeutix, Inc. $7,229.00 03/19/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239817
Principal investigator 1 Ocular Therapeutix, Inc. $5,633.20 03/19/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239819
Principal investigator 1 Ocular Therapeutix, Inc. $7,229.00 03/19/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239821
Principal investigator 1 Ocular Therapeutix, Inc. $3,000.00 03/19/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239823
Principal investigator 1 Ocular Therapeutix, Inc. $8,350.40 03/19/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239825
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,226.00 03/14/2025 Non-covered Recipient Entity
Sunil Gupta MD LLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364087
Principal investigator 1 Ocular Therapeutix, Inc. $8,000.00 03/14/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239813
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,000.00 03/13/2025 Non-covered Recipient Entity
RETINA SPECIALTY INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184173886
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,337.42 03/12/2025 Non-covered Recipient Entity
RETINA SPECIALTY INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184173810
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,337.42 03/12/2025 Non-covered Recipient Entity
RETINA SPECIALTY INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184173812
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,337.42 03/12/2025 Non-covered Recipient Entity
RETINA SPECIALTY INSTITUTE
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184173814
Principal investigator 1 Ocular Therapeutix, Inc. $26,613.90 02/07/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239791
Principal investigator 1 Janssen Research & Development, LLC $5,000.00 02/06/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC
Long-term Extension Study for Participants with Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) in JNJ-81201887 Parent Clinical Studies No dispute reported 06/30/2026 1175394436
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,070.00 01/31/2025 Non-covered Recipient Entity
Retina Specialty Institute-Pensacola
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1225405366
Principal investigator 1 Janssen Research & Development, LLC $1,396.00 01/27/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC
Long-term Extension Study for Participants with Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) in JNJ-81201887 Parent Clinical Studies No dispute reported 06/30/2026 1175394396
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,226.00 01/24/2025 Non-covered Recipient Entity
Sunil Gupta MD LLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364089
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,226.00 01/24/2025 Non-covered Recipient Entity
Sunil Gupta MD LLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250364091
Principal investigator 1 Ocular Therapeutix, Inc. $142.00 01/17/2025 Non-covered Recipient Entity
SUNIL GUPTA MD LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239789

Ownership and Investment Interests

One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together

Program yearMeasureAmountRecords
PY2024 Amount invested $12,781,971.00 2
PY2024 Value of interest $17,495,092.00 2
PY2023 Amount invested $1,428,704.00 2
PY2023 Value of interest $4,713,119.67 2
PY2022 Amount invested $0.00 2
PY2022 Value of interest $3,894,335.49 2
PY2021 Amount invested $0.00 3
PY2021 Value of interest $5,199,297.80 3
PY2020 Amount invested $0.00 3
PY2020 Value of interest $5,199,297.80 3
PY2019 Amount invested $0.00 3
PY2019 Value of interest $5,199,297.80 3

Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.

Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.

Ownership and Investment Interests records

Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them

15 records · PY2019–2024

Ownership and Investment Interests records (CSV)

Program yearCompanyAmount invested Value of interestTerms of interestInterest held by Dispute statusPublishedRecord ID
PY2024 US Retina LLC $12,615,798.00 $17,213,048.00 Membership Interest Physician Covered Recipient No dispute reported 06/30/2026 1143633984
PY2024 US Retina LLC $166,173.00 $282,044.00 Membership Interest Physician Covered Recipient No dispute reported 06/30/2026 1143634094
PY2023 US Retina LLC $1,410,360.00 $4,597,249.00 Membership Interest Physician Covered Recipient No dispute reported 06/30/2026 1052376417
PY2023 US Retina LLC $18,344.00 $115,870.67 Membership Interest Physician Covered Recipient No dispute reported 06/30/2026 1052376549
PY2022 US Retina LLC $0.00 $3,844,335.50 Shares Physician Covered Recipient No dispute reported 06/30/2026 951869117
PY2022 US Retina LLC $0.00 $49,999.99 Shares Physician Covered Recipient No dispute reported 06/30/2026 951869331
PY2021 US Retina LLC $0.00 $3,844,335.50 Shares Physician Covered Recipient No dispute reported 06/30/2026 856668645
PY2021 US Retina LLC $0.00 $49,999.99 Shares Physician Covered Recipient No dispute reported 06/30/2026 856668815
PY2021 US Retina LLC $0.00 $1,304,962.31 Shares Physician Covered Recipient No dispute reported 06/30/2026 856669241
PY2020 US Retina LLC $0.00 $3,844,335.50 Shares Physician Covered Recipient No dispute reported 06/30/2026 714310945
PY2020 US Retina LLC $0.00 $49,999.99 Shares Physician Covered Recipient No dispute reported 06/30/2026 714311115
PY2020 US Retina LLC $0.00 $1,304,962.31 Shares Physician Covered Recipient No dispute reported 06/30/2026 714311537
PY2019 US Retina LLC $0.00 $3,844,335.50 Shares Physician Covered Recipient No dispute reported 06/30/2026 655842091
PY2019 US Retina LLC $0.00 $49,999.99 Shares Physician Covered Recipient No dispute reported 06/30/2026 655842425
PY2019 US Retina LLC $0.00 $1,304,962.31 Shares Physician Covered Recipient No dispute reported 06/30/2026 655843279